Doxorubicin
| Code | Size | Price |
|---|
| TAR-T1456-10mg | 10mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Doxorubicin is a Topoisomerase II (Top2) inhibitor with antineoplastic activity.
CAS:
23214-92-8
Formula:
C27H29NO11
Molecular Weight:
543.525
Pathway:
DNA Damage/DNA Repair
Purity:
0.98
SMILES:
COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
Target:
Topoisomerase
References
1. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50.
2. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33.
3. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2.
4. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32.
5. Liang L, Tu Y, Lu J, et al. Dkk1 exacerbates doxorubicin-induced cardiotoxicity by inhibiting Wnt/?-catenin signaling pathway[J]. J Cell Sci. 2019 May 16;132(10).